TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2680793

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 151

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both Omeprazole and Ranitidine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 151
Study: 62161

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31115844

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus everolimus
Number of subjects: 133

Group type: COMPARATOR
Intervention: Vinorelbine monotherapy
Number of subjects: 133
Study: 29161288

Group type: EXPERIMENTAL
Intervention: Maraviroc with darunavir/ritonavir qd
Number of subjects: 115

Group type: COMPARATOR
Intervention: Continuation of current ART
Number of subjects: 115
Study: 24379454

Group type: EXPERIMENTAL
Intervention: Standardized music therapy anger management program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 14
Study: 24123845

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone and Nestorone treatment after 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum Nestorone concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum testosterone concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early suppression of gonadotropins
Number of subjects: 0
Study: 21904235

Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Static stretching (SS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 60
Study: 17881423

Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Twice-Normal Saline (2NS)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS) at home testing
Number of subjects: 4
Study: 16055070

Group type: EXPERIMENTAL
Intervention: Free sorting task of material samples
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Physical measurements of compressibility and roughness
Number of subjects: 124
Study: 12847153

Group type: EXPERIMENTAL
Intervention: Thalamic cholinergic terminal density measured with [123I]IBVM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Striatal monoaminergic terminal density measured with [11C]DTBZ
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal control subjects scanned with [123I]IBVM
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal control subjects scanned with [11C]DTBZ
Number of subjects: 13
Study: 10960942

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study: 8618474

Group type: EXPERIMENTAL
Intervention: High-dose ara-C (HIDAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard induction treatment (implied control)
Number of subjects: 0
Study: 1579228

Group type: EXPERIMENTAL
Intervention: Intrathecal thyrotropin-releasing hormone (TRH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study: 4081627

Group type: EXPERIMENTAL
Intervention: Maprotiline (1 mg/kg/h for 60 min, then 2 mg/kg/h until 180 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 12
Study: 29078054

Group type: EXPERIMENTAL
Intervention: Interactive Option Grid decision aids for Breast cancer, PSA, and Statins
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Interactive Option Grid decision aids
Number of subjects: 626
Study: 27160380

Group type: EXPERIMENTAL
Intervention: Sulodexide 500 lsu/day for 1 year (Group 3)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sulodexide 1000 lsu/day for 6 months followed by 250 lsu/day for 6 months (Group 4)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control Group 1 (blank)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control Group 2 (250 lsu/day for 1 year)
Number of subjects: 79
Study: 25345483

Group type: EXPERIMENTAL
Intervention: Posterior approach for hip replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lateral approach for hip replacement
Number of subjects: 0
Study: 23377602

Group type: EXPERIMENTAL
Intervention: Short-Term Token Economy (STTE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 20493637

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 IU
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18634956

Group type: EXPERIMENTAL
Intervention: Neuro-reflexotherapy intervention (NRT) - 2 treatments, one immediately after baseline assessment and another 45 days later.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham intervention (control group) - placement of epidermal devices within a 5-cm radius of target zones.
Number of subjects: 51
Study: 16237621

Group type: EXPERIMENTAL
Intervention: Individualized training exercise at the ventilatory threshold (VT) intensity for 12 weeks in T-CHD group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 17
Study: 12081734

Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening for abdominal aortic aneurysm (AAA)
Number of subjects: 6058

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 6058
Study: 9931835

Group type: EXPERIMENTAL
Intervention: Mechanical methods for thromboembolism prevention (intermittent pneumatic compression, A-V impulse systems, ankle motion devices)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional prevention (pharmacological and physical)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional prophylaxis supplemented with mechanical prophylaxis
Number of subjects: 0
Study: 8564883

Group type: EXPERIMENTAL
Intervention: Propranolol (60 mg for females, 80 mg for males)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cold exposure (5 degrees C)
Number of subjects: 9
Study: 12282175

Group type: EXPERIMENTAL
Intervention: 600 mg of RU 486 + 500 mg of sulprostone (Nalador) administered intramuscularly
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: RU 486 alone
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Complete protocol (RU 486 + sulprostone)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 354
Study: 364625

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Selective vagotomy with pyloroplasty (SV + P)
Number of subjects: 50
Study: 6459357

Group type: EXPERIMENTAL
Intervention: Combination of 60 micrograms ipratropium bromide and 200 micrograms of fenoterol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lower dose combinations or either drug alone
Number of subjects: 18
Study: 30786902

Group type: EXPERIMENTAL
Intervention: Active 1+FUN intervention (ten-session intervention over approximately six months)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Active 1+FUN intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention for one year)
Number of subjects: 204
Study: 30526600

Group type: EXPERIMENTAL
Intervention: Higher levels of total physical activity (PA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour (SB)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour (SB) in combined model
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Higher BMI or FMI
Number of subjects: 600
Study: 27567063

Group type: EXPERIMENTAL
Intervention: Controlled motivation for healthy eating
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Autonomous motivation for healthy eating
Number of subjects: 90
Study: 24473704

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation for 8 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (Group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No zinc supplementation (Group B)
Number of subjects: 58
Study: 20835926

Group type: COMPARATOR
Intervention: Esophageal stenting alone (Group I)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of stenting and external beam radiotherapy (Group II)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Group II (after radiotherapy)
Number of subjects: 84
Study: 21146675

Group type: EXPERIMENTAL
Intervention: Clopidogrel (started after surgery for 30 days) + Aspirin 81 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo + Aspirin 81 mg daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clopidogrel + Aspirin 81 mg daily
Number of subjects: 100
Study: 17923056

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 15670002

Group type: EXPERIMENTAL
Intervention: Highest tertile of caloric intake (mean intake close to prescribed intake)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tertiles of caloric intake
Number of subjects: 62
Study: 11915041

Group type: EXPERIMENTAL
Intervention: High dose peginterferon alfa-2b (3 microg/kg for 1 week, 1.5 microg/kg for 3 weeks, and 1.0 microg/kg for 44 weeks) plus 800 mg ribavirin daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low dose peginterferon alfa-2b (0.5 microg/kg for 48 weeks) plus 800 mg ribavirin daily
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High dose peginterferon alfa-2b
Number of subjects: 55
Study: 9814337

Group type: EXPERIMENTAL
Intervention: Empowerment teaching method
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 74
Study: 9373378

Group type: EXPERIMENTAL
Intervention: Social support specific to exercise
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Initial support from exercise staff
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Support from family and friends and exercise staff at Month 6
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Home-based exercise programs
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Divorced nonsmokers
Number of subjects: 269
Study: 2503018

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 200 mg three times daily with GTN 20 mg transdermal/24 h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo with GTN 20 mg transdermal/24 h
Number of subjects: 8
Study: 322243

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Aspirin (3.6 g daily)
Number of subjects: 28
Study: 31101083

Group type: EXPERIMENTAL
Intervention: SpHb monitoring
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard-care (without SpHb monitoring)
Number of subjects: 69
Study: 27890648

Group type: EXPERIMENTAL
Intervention: Bupropion sustained release (150 mg, twice a day for 12 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 26445318

Group type: EXPERIMENTAL
Intervention: Usual care plus a 12-week supervised exercise programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (compression only)
Number of subjects: 80
Study: 23978323

Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Let's Talk About the Children (LTC)
Number of subjects: 145
Study: 21245130

Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration (HDF)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low-flux haemodialysis (HD)
Number of subjects: 69
Study: 19817198

Group type: EXPERIMENTAL
Intervention: Exercise therapy after selective posterior rhizotomy (SPR)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Selective posterior rhizotomy (SPR) only (Control)
Number of subjects: 226
Study: 18184041

Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg/day for 3 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 15066870

Group type: EXPERIMENTAL
Intervention: Priorix
Number of subjects: 49

Group type: COMPARATOR
Intervention: M‐M‐R II
Number of subjects: 49
Study: 10677821

Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CQI
Number of subjects: 0
Study: 9355902

Group type: EXPERIMENTAL
Intervention: Abl+Pm (AV junction ablation and DDDR mode-switching pacemaker)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pharmacological treatment (Control)
Number of subjects: 43
Study: 7692455

Group type: EXPERIMENTAL
Intervention: Iloprost (daily infusions of 6 hours)
Number of subjects: 267

Group type: COMPARATOR
Intervention: PGE1 (2 x 2 hours infusions)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 267

Group type: COMPARATOR
Intervention: PGE1
Number of subjects: 267
Study: 3513518

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Propranolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31488098

Group type: EXPERIMENTAL
Intervention: Iron-fortified milk with 1.2 mg/100 mL of iron
Number of subjects: 133

Group type: COMPARATOR
Intervention: Iron-fortified milk with 0.4 mg/100 mL of iron
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both interventions (1.2 mg and 0.4 mg of iron)
Number of subjects: 133
Study: 27037849

Group type: EXPERIMENTAL
Intervention: NBI target biopsy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Regular biopsy
Number of subjects: 138
Study: 26565082

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium bifidum W23, Bifidobacterium animalis subsp. lactis W52, Lactococcus lactis W58, EcologicPanda)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 0
Study: 23711288

Group type: EXPERIMENTAL
Intervention: Dearterialization (with Doppler guidance and mucopexy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haemorrhoidectomy
Number of subjects: 40
Study: 21261482

Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 82

Group type: COMPARATOR
Intervention: Vacuum-formed retainer
Number of subjects: 82
Study: 18188489

Group type: EXPERIMENTAL
Intervention: TVT‐O procedure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Monarc procedure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Inside-out procedure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Outside-in procedure
Number of subjects: 120
Study: 16484822

Group type: EXPERIMENTAL
Intervention: Autologous whole blood (AWB) injections, 8 weekly intramuscular injections
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study: 12635675

Group type: EXPERIMENTAL
Intervention: 25% aminocaproic acid (ACA) in CPM gel
Number of subjects: 132

Group type: COMPARATOR
Intervention: cycloplegic drops only
Number of subjects: 132

Group type: COMPARATOR
Intervention: 2% carboxy polymethylene (CPM) gel as placebo
Number of subjects: 132
Study: 10372738

Group type: EXPERIMENTAL
Intervention: CRH + DDAVP
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CRH
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8669413

Group type: EXPERIMENTAL
Intervention: Low-fiber diet followed by labeled low-fiber test meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fiber-supplemented diet followed by labeled oat bran test meal
Number of subjects: 6
Study: 1812478

Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 21
Study: 6872291

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propranolol and its metabolites
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Naphthoxylactic acid
Number of subjects: 28
Study: 31566149

Group type: EXPERIMENTAL
Intervention: Dilution rate 1:4
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Equilibration time 1 h
Number of subjects: 4
Study: 28506956

Group type: EXPERIMENTAL
Intervention: iCBT (internet-based cognitive behavioral therapy)
Number of subjects: 91

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 91
Study: 27746112

Group type: EXPERIMENTAL
Intervention: Optimum intravenous busulfan AUC of 78–101 mg×h/L
Number of subjects: 674

Group type: COMPARATOR
Intervention: Low historical target of 58–86 mg×h/L
Number of subjects: 674

Group type: COMPARATOR
Intervention: High busulfan AUC (>101 mg×h/L)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Low AUC (<78 mg×h/L)
Number of subjects: 674
Study: 24670970

Group type: EXPERIMENTAL
Intervention: High-dose freeze-dried strawberries (HD-FDS; 50 g/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose freeze-dried strawberries (LD-FDS; 25 g/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-dose control (HD-C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose control (LD-C)
Number of subjects: 60
Study: 22853453

Group type: EXPERIMENTAL
Intervention: Rusch intubation stylet (Group S)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 103
Study: 20477765

Group type: EXPERIMENTAL
Intervention: Brief intervention for unhealthy alcohol use
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Alcohol-attributable principal admitting diagnosis
Number of subjects: 341

Group type: COMPARATOR
Intervention: Alcohol dependence or high problem perception
Number of subjects: 341
Study: 17622238

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 26

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 26
Study: 15826438

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 32
Study: 12166542

Group type: EXPERIMENTAL
Intervention: Donepezil (up to 10 mg once daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Rivastigmine (up to 6 mg twice daily)
Number of subjects: 111
Study: 10223557

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg twice daily)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 7784338

Group type: EXPERIMENTAL
Intervention: Gamma scintigraphy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pharmacokinetic (charcoal-block) method
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: pMDI with slow inhalation (27 l/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: pMDI with fast inhalation (151 l/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebuhaler large volume spacer device (average inhaled flow 17 l/min)
Number of subjects: 8
Study: 1519031

Group type: EXPERIMENTAL
Intervention: Ivermectin 100 mcg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 3 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DEC 3 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DEC 6 mg/kg
Number of subjects: 58
Study: 6375756

Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride 24 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ambroxol 90 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: alpha-Chymotrypsin buccle 100 ch.u. per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serratiopeptidase 30 mg per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 31483785

Group type: EXPERIMENTAL
Intervention: Organic diet for 40 days
Number of subjects: 149

Group type: COMPARATOR
Intervention: Conventional diet for 40 days
Number of subjects: 149
Study: 29573657

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 32
Study: 25584994

Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic neuropathy
Number of subjects: 635

Group type: COMPARATOR
Intervention: Erectile dysfunction and lower urinary tract symptoms
Number of subjects: 635
Study: 23630210

Group type: EXPERIMENTAL
Intervention: 3× HD‐AraC (high-dose cytarabine consolidation with three cycles of 18 g/m(2))
Number of subjects: 1179

Group type: COMPARATOR
Intervention: MAC/MAMAC/MAC (multiagent consolidation with two cycles of mitoxantrone 30 mg/m(2) plus cytarabine 12 g/m(2) and one cycle of amsacrine 500 mg/m(2) plus cytarabine 10 g/m(2))
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: 3× HD‐AraC
Number of subjects: 1179

Group type: COMPARATOR
Intervention: MAC/MAMAC/MAC
Number of subjects: 1179
Study: 21336959

Group type: EXPERIMENTAL
Intervention: Ileal orthotopic neobladder (ONB)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Uretero-ureterocutaneostomy (UUC)
Number of subjects: 39
Study: 19226239

Group type: EXPERIMENTAL
Intervention: Home-based strength training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Home-based balance training
Number of subjects: 48
Study: 17099670

Group type: EXPERIMENTAL
Intervention: Orofacial trauma‐based brief intervention (visual presentation with information and photographs)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 242
Study: 15306031

Group type: EXPERIMENTAL
Intervention: Aerobics in bright light
Number of subjects: 98

Group type: COMPARATOR
Intervention: Aerobics in normal room lighting
Number of subjects: 98

Group type: COMPARATOR
Intervention: Relaxation/stretching in bright light
Number of subjects: 98
Study: 11301186

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor mobilization
Number of subjects: 50
Study: 8770427

Group type: EXPERIMENTAL
Intervention: Consumption of more than 25 tablets
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Loose preparation of tablets
Number of subjects: 80

Group type: COMPARATOR
Intervention: Blister-pack preparation of tablets
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Warning labels
Number of subjects: 80